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Alzheimer’s: A Tale of Two Diseases   
 
Alzheimer’s disease (AD) is unique in that multiple paths can lead to its manifestation. 
There are numerous risk factors that increase the susceptibility to AD and a vast number of 
combinations may lead to its acquisition. Additionally, the underlying mechanism by which the 
illness manifests itself could possibly differ amongst varying patients. It is my contention that 
early on-set Alzheimer’s can be categorized as a unique illness in respect to late on-set AD, due 
to vastly different etiologies, although symptoms are similar. It will be demonstrated that early 
on-set AD is largely a genetically based etiology with little that can be done for prevention. Late 
on-set AD tends to be due to chronic environmental factors which preventative measures could 
have stifled. In addition, just as there is a need to have fuller characterization of Dementia, I will 
defend the position that AD treatment will benefit from more precise categorization as well as 
raise the ethical repercussions that follow. Lastly, the position for maintaining the illness under 
the singular name AD will also be considered for its pros and its ethical consequences. 
Somewhat tangentially, but important nonetheless, is the importance of noting that this paper in 
no fashion will take the position that genetics and the environment do not play roles in both 
illnesses, but rather it will be articulate that they play roles of unique and varying degree in each.   
AD was discovered by Alois Alzheimer but named by Dr. Kraeplin in the 8th edition of 
his Handbook of Psychiatry (Maurer K.; Maurer U., 2003). Dr. Alzheimer was a German 
psychiatrist as well as neuropathologist who came to be interested in lab work for senile illnesses 
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(Engstrom, E.J. 2007). The original specimens on which Dr. Alzheimer had based his original 
conclusions on were reanalyzed, amidst some controversy over AD, in the late 90’s. The 
reanalysis revealed Alois Alzheimer to be correct in his characterization of AD in his historical 
patient. The patient, 56-year-old Johann F., was observed to have the AD related apolipoprotein 
allele epsilon-3 (Graeber, M., Kösel, S., Egensperger, R. et al, 1997). Dr. Alzheimer came to be 
reaffirmed as the discoverer of the illness and the field began to move even further in its 
characterization of the disease. Alzheimer’s disease diagnoses have been update since their 
inception, now having three separate medical characterizations. Amongst the three are the 
dementia stage, the symptomatic pre-dementia phase, and lastly the asymptomatic preclinical 
phase. Historically, AD was thought to have a synonymous presentation of symptoms and 
underlying pathology. This was later discovered to not be the case, through further AD research 
it has become evident that underlying pathology can be asymptomatic; essentially observed 
through diffuse amyloid plaques being present with no manifested AD symptoms. Such 
scenarios led to the updating of the NIA-Reagan Institute criteria for the diagnoses of AD. 
Neuropathologically, AD has always been diagnosed through observation of at least a moderate 
amount of neuritic plaques in the neocortex containing Beta-amyloid, and regional distribution of 
neurofibrillary tangles, through the use of a low-power microscope. Over the years, AD 
diagnoses became more nuanced with a scale amended to diagnoses in 1984 to denote severity of 
impairment due to the illness. Additionally, over the time common comorbidities of AD with 
other cognitive illnesses (i.e. Lewy body disease) came to also be acknowledged. Presently, the 
most widely studied biomarkers of AD are AB accumulation now observed through PET 
imaging, neuronal degeneration, tau deposits (usually elevated in the CSF), as well 
neurofibrillary tangles (Jack, C. et al. 2011).       
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Notably, the most common form of Dementia is Alzheimer’s disease with a 3.9% global 
prevalence amongst people older than 60, as of 2014. While Dementia is mostly known as a 
general cognitive decline, AD differs in that it is accompanied by a much more acute loss of 
cognition and memory. Additionally, AD physiologically presents with beta-amyloid plaques, 
NFT’s, and a host of other characteristics (Ng, K., Ng, A., Assam, P., Heng, E., Kandiah, N., 
2014). The term Dementia conservatively includes AD, vascular dementia, dementia with Lewy 
bodies, and frontotemporal dementia (Kawamura, T., Umemura, T., Hotta, N., 2012). Dementia 
can however, be broadened to include Parkinson’s disease, Creutzfeldt-Jakob disease, 
Huntington’s disease, and Wernike-Korsakoff Syndrome, (http://www.alz.org/dementia/types-
of-dementia.asp) and is somewhat commonly done so in some branches of medicine. As more 
information is divulged it becomes more and more evident that specificity in the world of 
dementia is crucial. Each particular type of dementia has a unique underlying etiology with a 
distinctive pathology. The cognitive impairment of AD is most likely due to the synergistic 
effects of several factors. Amongst these various disease factors are beta-amyloids building up 
and elongated unbranched protein fibrils as critical factors (Riek, R., Eisenberg, D. S., 2016). As 
diffuse beta amyloid aggregate into senile plaques researchers took it unto themselves to make 
sense of why. It turns out that it is possibly due to a lack of perfusion in the brain, as observed in 
a study of patients with critical stenosis. 15 out of 20 patients studied showed plaque deposits, 
most often in the depths of the gyri. (Armstrong, 2013). However, brain perfusion is but one of 
several possible etiological agents. There are several possible etiological agents for Alzheimer’s, 
which generally fall within two categories: genetic or environmental. Genetic marker examples 
include mutations in the PSEN gene while, environmental factors include examples like insulin 
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resistance. The discovery that early onset AD is mostly a genetically based phenomenon, while 
late onset AD tends to differ in its origin makes a strong point to revisit how we think of AD.  
 
Case for early on-set being mostly genetically based 
Genetic factors seem to be central to the pathology underlying early onset AD. It has been 
shown that “rare mutations in three genes – APP, PSEN1, and PSEN2 – are associated with 1% 
of AD and other frequent genetic variants such as APOE-E4 can account for up to 20% of total 
cases of the disease” (Sanchez-Mut, J.V., Graff, J., 2015). The statistics still leave at least, 
assuming no overlap between mutations, that 79% of AD has a non-genetically linked etiology. 
To begin with mutations of amyloid precursor protein (APP), the mutation can lead to a greater 
susceptibility of beta-amyloid build up and coincidently, lack of its clearance (Armstrong, 2013). 
A variety of AB peptides are formed as a result of secretase cleavage of APP, the most common 
peptide being AB42. The amyloid Cascade Hypothesis (ACH) proposes that the deposition of AB 
peptide acts as the initial pathological event in AD, leading to the formation of senile plaques 
(SP) and neurofibrillary tangles (NFT), summing up in cell death and dementia. Both SP and 
NFT acquire several additional proteins during their formation, such as Apo E, ubiquitin, and 
their complement. The ACH theory has found support in experiments with transgenic mice 
expressing elevated levels of APP resulting in AB deposition, synaptic loss, and gliosis 
(Armstrong, 2013). The first objection ACH theory receives from critics is the fact that SP and 
NFT may prove to be reactive products that result from cellular neurodegeneration, rather than 
being the cause itself. However, it is important to note that inflammation of the microglia is 
caused by overload of SP’s and NFT’s around the neurons to the point of toxicity. Therefore, 
there is still some merit to the discussion between accepting the theory or not, at least in respect 4
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to the degree of ambiguity that persists. The second objection to the theory is how ACH is not a 
generally accepted mechanism to explain how AB deposition leads to NFT. The presence of tau 
is necessary for AD pathology, thus its subsequent lack of mention in the ACH model seems to 
denote an incomplete explanation. 
Moreover, the Presenilin (PSEN) gene mutation has been greatly associated with an 
increased likelihood for early-onset AD. Interestingly enough, the most common type of FAD 
has been linked to mutations of the PSEN genes (Armstrong, 2013). Additionally, another 
genetic marker identified for AD is an allelic variation in apolipoprotein (Apo E). This epsilon 4 
allele is a major risk factor in late-onset AD, having a 2-3 time increase in frequency within the 
individual with AD (Armstrong, 2013). Of note, is the fact that people with diabetes are reported 
to have a significantly low incidence of the APOE epsilon 4 allele but diabetes itself still proves 
to be a risk factor for AD (Farris, W., et. al., 2002). Some controversy has arisen on the topic of 
the APO E allele and its AD association due to an opposing study finding no significant support 
for E318G acting as a risk factor for AD in the APOEe4 carriers (Hippen, et.al. 2016). 
Additionally, the chromosomal locus 12q13, the region that encompasses the vitamin D receptor 
(VDR) gene has been implicated as risk factor for AD (Armstrong, 2013).   
 
Case for late on-set being mostly environmentally based 
The majority of AD illnesses have by and large had stronger environmental ties than 
genetic. While several genetic alterations have been associated with AD, research has shown the 
vast majority of AD cases to not have strong genetic underpinnings rather they are considered as 
a consequence of non-genetic factors (Sanchez-Mut, J.V., Graff, J., 2015). A major aspect of AD 
5
Rivera: Alzheimer's: A Tale of Two Diseases
Published by DigitalCommons@SHU, 2017
Rivera 6 
 
pathology has come to widely be thought of as due to faulty beta-amyloid metabolism, be it from 
overproduction or poor clearance. Research has suggested that familial, early-onset AD is 
characterized more so by overproduction of AB42, while late-onset AD is characterized by a 
faulty AB clearance mechanism. Genetically, late-onset AD is associated with e4 allele of the 
apolipoprotein E gene, a major risk factor for issues involved with AB trafficking (Jack, C. et al. 
2011). While the non-genetic factors in which epigenetics are thought to play a role are diabetes 
mellitus, hypertension, obesity, physical activity, depression, smoking as well as low educational 
attainment, amongst others (Sanchez-Mut, J.V., Graff, J., 2015). A possible 
environmental/epigenetic theory has risen stating in its Latent Early life Associated Regulation 
(LEARn) model that a series of harmful events from gestation to old age may accumulate as 
epigenetic markers possibly inducing or accelerating AD manifestation. However, epigenetic 
correlation has yet to be proven as causal and as such, the question remains between whether 
epigenetic modifications are driving the chromatin behavior or if they are just a consequence of 
the other processes happening nearby (Sanchez-Mut, J.V., Graff, J., 2015). 
Moreover, amongst all the researched possible environmental causal agents of AD 
perhaps none can match Aluminum in the amount of interest and controversy it has received. 
Aluminum has become one of the most researched possible environmental etiological agents for 
AD. It is important to note that there is no known physiological role for Al within the body 
(Nayak, 2001). Additionally, Al is the most abundant neurotoxic metals on the planet. Only 
small amounts of Al are needed to produce neurotoxicity in the human body, which can be 
satisfied through small dosing in dietary Al intake. Experimental evidence has repeatedly 
demonstrated that chronic Al intoxication reproduces neuropathological hallmarks of AD 
(Tomljenovic, 2011). However, the efficacy of such experiments have been questioned as well as 
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their reproducibility. Already damaged brains may be susceptible to the accumulation of Al, 
muddying the significance of many studies because much research has been conducted in the 
already AD effected brain. On the other hand, most studies have however, shown enhanced 
amounts of Al in the AD brain. But as with most controversial topics there are opposing studies 
and this one exposed high concentrations of Al to patients with renal failure resulting in no 
cellular NFT development. Acute Al doses have, however been shown to be neurotoxic 
(Armstrong, 2013). Perhaps Al plays a role in the degree of aggression manifested by AD? A 
study showed that red blood cell aggregation increased significantly in Aluminum Trichloride-
induced Alzheimer’s disease (Chen, et. al. 2013). Such a study has possible implications on AD 
being concordant with vascular dementia due to red blood cell clotting. Additionally, studies 
have researched whether Al having passed through the blood brain barrier may cause an immune 
response perhaps leading to an autoimmune response that manifests into AD or at the very least 
plays a partial causative role (Armstrong, 2013). Of course claims are easier to make than defend 
and as such further research is necessitated. Topics requiring more research are the organ-
specific variations in Al toxicity as well as the kinetics of Al in these varied environments 
(Nayak, 2001). Lastly, it is important to examine any possible modifying effects other elements 
within the body may have on Al or vice versa (Frisardi, 2010).  
Another possible etiological agent that has been considered is a direct physical injury 
causing tissue damage. Such an event could result in Hydrocephalus ex-vacuo, a buildup of 
cerebrospinal fluid (CSF). Not only would the original injury then result in tissue damage but the 
increase in pressure would continue to have an injurious effect. Additionally, inflammatory 
cytokines could spread amplifying the original injury. Survivors of head injuries tend to 
demonstrate what may be an acute phase response to neuronal injury, of overexpression of APP 
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leading to deposition of AB. Formation of pathological proteins as a result of head injury may be 
one method by which AD pathology develops and it would propagate via cell to cell transfer 
through tubulin tracks (Armstrong, 2013). 
Malnutrition has also been considered as a possible etiological agent. Development of 
NFT has been hypothesized to be due to chronic nutritional deficiencies of Ca and Mg. The 
problem with malnutrition as an etiological agent, however is that malnutrition could prove to be 
a mere consequence of the disease that resulted from the mental state of the patient. Direct 
dietary experiments have been conducted to test the hypothesis of malnutrition’s role in causing 
AD. In one experiment, rabbits were fed with high levels of dietary cholesterol which resulted in 
the induction of AB deposits which accumulated and aggregated. Additionally, a human family 
carrying a mutation of APP gene (APP71) carriers, which results in a protein change of Valine to 
Glycine, were shown to have a greater B12 deficiency as compared to non-carrier family 
members. B12 deficiency could then be theorized to cause a reduction of monoamine 
transmitters and subsequently a reduction in cholinergic activity (Armstrong, 2013).   
Moreover, AD has also been considered to be greatly affected by aging, and prove to 
possibly be an exacerbation of aging. With the present state of technology people are simply 
living much longer lives now when compared to the past. Currently life expectancy has risen in 
the United States to roughly 78.8 – 78.9 years according to an NPR piece (Rob Stein, 2016). Age 
may be the culprit in making the present moment have dementia as the fifth leading cause of 
death in “high-income countries” (Elie Dolgin, How To Defeat Dementia: The three things that 
could help prevent a meltdown in health-care systems worldwide). Research has shown that 
myelin loss is secondary to neuronal degeneration, this finding is suggestive of an age related 
loss of myelin. In addition, the loss of cells in the locus caeruleus (LC) diminishes the amount of 8
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noradrenaline provided to the cortex via terminal varicosities. Noradrenaline is an integral 
stimulative factor in activating microglia to suppress production of Amyloid Beta plaques 
(Armstrong, 2013). With the reduction in noradrenaline AB plaques are free to aggregate and if 
medicine already pushes people to live to the brink of the body’s capacity then in accordance 
with the age theory, AD is bound to occur.  
Infectious agents have also been implicated as a possible etiological agent that may very 
well culminate in full manifestation of AD. The virus herpes simplex (HSV) may do so by 
leading to antibody movement into the cerebral spinal fluid (CSF), inducing abnormal protein 
formation resulting in Plaque formation as well as NFT and possibly full on AD manifestation. 
Marked structural and biochemical alterations have been observed in regions associated with 
olfaction, i.e. olfactory bulb and EC (Armstrong, 2013). HSV1 infection is thought to induce 
AD-like tau phosphorylation at several sites. The virus is has been observed to activate glycogen 
synthase kinase 3B and protein kinase A, the enzymes that cause phosphorylation at several sites 
that can result in neurofibrillary tangles (Wozniak, Frost, and Itzhaki, 2009).   
Moreover, a defective endosomal sorting and/or trafficking as well as lysosomal 
dysfunction are thought to be other possible physiological pathologies researched under AD 
interest. They have been implicated by AD research to be possible etiologies or at the very least 
important symptoms to note, particularly as a site for therapy. As a possible etiological cause, 
researchers theorize that AB accumulates due to a dysfunction in the late autophagy stages of the 
pathways. The defunct pathways would lead to an inefficient clearance of autophagic vacuoles, 
resulting in progressive build up and illness manifestation (Peric & Annaert, 2015). 
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Historical degenerative anatomical pathways that have been of interest in AD 
research. 
The degeneration of anatomical pathways is significant and as such must be touched upon 
when speaking on the topic of AD. The Cholinergic pathway is one of the pathways historically 
scrutinized by AD research scientists. AD is characterized by a profound degeneration of 
cortically projecting cholinergic neurons of the basal forebrain as well as an associated depletion 
of cortical cholinergic activity. Interestingly enough, it seems that the degeneration of the 
cholinergic pathway is exacerbated when the patient also has trisomy 21 (Grothe, et.al. 2014). 
Several post-mortem studies have shown significant loss of acetylcholine in the AD patient’s 
brain. Additionally, 50 to 70% reductions in choline acetyltransferase (CAT) as well as 
reductions in acetylcholinesterase (late in the disease) were found. The fact that some of this data 
comes post-mortem means that the data cannot be taken at face value due to the significant 
changes that tend to occur at the extremes of life. Undoubtedly, degeneration of the cholinergic 
system occurs in AD. However, multiple neurotransmitter deficits are common in AD. Thus 
researchers believe there must be an underlying issue causing AD manifestation and the 
deterioration of this pathway (Armstrong, 2013). An interesting note to make is how ethanolic 
extracts of Phyllanthus emblica (EEPA) ripe fruits have shown positive effects on the brain via 
antioxidant mechanisms which decrease acetylcholinesterase activity in rats, this may serve as a  
possible treatment for AD or at least a treatment for the deterioration specific site of Cholinergic 
pathway (Uddin, 2016). 
The cortico-cortical pathway is another anatomical pathway that has been researched to 
determine its role as a possible major factor in the AD pathology. The pathway in the AD brain 
is characterized by loss of synaptophysin reactivity in the cortex, which relates to synapse loss in 10
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the temporal lobe. Additionally, decrease in the synaptic marker SP6 has been observed in all 
regions of the AD brain. NFT was also observed in the cell bodies that give rise to the cortico-
cortical pathways. It is theorized that a possible mode of disease spread could be in an 
orthograde or retrograde fashion. Studies have reported that tau and AB could exit cells via 
exocytosis and enter new cell via endocytosis, essentially traveling via a cellular highway. 
Protein transfer has also been shown to be able to occur in a much more direct manner, via 
tunneling nanotubes (TNT). With such a diverse and wide spread mechanism of protein travel it 
may prove the case that only stifling AD’s point of origin rather than its spread could prove 
feasible. Moreover, another systemic point of interest in AD is mitochondrial metabolic 
dysfunction. This organelle based theory has also be implicated as a possible etiological agent to 
consider when studying AD. Early change in AD is characterized by swollen and distorted 
mitochondria, accompanied by cerebral metabolic decline. Such a finding led to the hypothesis 
being formed and labeled the Mitochondrial Cascade Hypothesis (MCH) (Armstrong, 2013). 
 
Ethical reasoning and considerations for one illness versus two 
As is the case with most pursuits of science, how we go about them is laden with much 
meaning. The organization of Alzheimer’s may prove to be no different and depending on how it 
is done it can potentially lead to greater clarity in publications as well as efficacy in studies. By 
distinguishing late onset from early onset, prevention may become much more compelling due to 
the vast prevalence of late onset AD which seems to be mostly caused by life events and choices. 
The treatment of late on-set AD as a distinct illness would serve to elucidate how prevention is 
key, and in doing so possibly necessitate legislation that would go against the food industry, i.e. 
sugar consumption.  11
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On the other hand, the solidarity that comes from shared experience is known to lead to 
normalizing of large diseases, not in the sense that illness is normal but rather in the sense of 
breaking stigmas associated with the illness of interest. In the same fashion in which cancer was 
brought into the public light and garnered support, it is possible the same could be done with 
AD. Such an occurrence would make AD more financially strong making the fight for a cure 
more feasible. Support could possibly be easier to gain through a unified illness, that way the 
illness is seen as more prevalent raising more concern and with it greater funding. This is in 
accordance with the historical example of cancer, a general term encompassing a wide range of 
illnesses (Mukherjee, S. (2010). The emperor of all maladies: A biography of cancer. New York: 
Scribner). At the current moment $700 million is spent as annual funding by the NIH for 
Dementia, as of 2015, which is quite small compared to the $2 billion for cardiovascular disease 
and $5 billion for cancer. Importantly however, more money is being demanded as people begin 
to speak out more and the illness gets more public attention. (Elie Dolgin, How To Defeat 
Dementia: The three things that could help prevent a meltdown in health-care systems 
worldwide). Thus, the ethical considerations for the illness to be unified under one term must 
also be considered. Pairing Dementia and AD, at least amongst the public’s eye, could have a 
positive economic effect for those committed to AD research. Projections for the year 2050 have 
Dementia effecting roughly 130 million and costing the American tax payers an estimated $1 
trillion per year (Elie Dolgin, How To Defeat Dementia: The three things that could help prevent 
a meltdown in health-care systems worldwide).  
 According to George Vradenburg, chair and co-founder of the non-profit 
UsAgainstAlzheimer’s, there is a stigma attached to the illness. In addition, the family caregivers 
tend to be overworked and too exhausted to be motivated enough to speak up. The tables are 
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turning for the patients, however, with social and political awareness increasing in the past five 
years (Elie Dolgin, How To Defeat Dementia: The three things that could help prevent a 
meltdown in health-care systems worldwide). Thinking of AD as a more severe form of 
Dementia is beneficial, bolstering the urgency to address Dementia economically as well as 
increasing the empathy for Alzheimer’s patients. Robert Egge has an interesting opinion on the 
future relationship betweem AD and the public. The chief public policy officer of the 
Alzheimer’s Association, does not believe people will have the choice when it comes to 
accepting the reality of Dementia. He believes that in just a few short decades, everyone will 
have a friend or loved one with the disease, essentially forcing the public to pay attention to its 
existence (Elie Dolgin, How To Defeat Dementia: The three things that could help prevent a 
meltdown in health-care systems worldwide). 
 
The general ethics of AD 
The ethical responsibility to few issues are as clear cut as is treating Alzheimer’s as 
quickly and aggressively as possible. Ethics concerns itself with who we ought to become as 
individuals and how we ought to act in relationship to others (Panicola, M. R., 2011, Health Care 
Ethics). How that may be applied to Alzheimer’s is clear, by asking ourselves towards what ideal 
society we want to proceed. Our society is one built on aspirations of complete egalitarianism, 
and as such we should make decisions to progress towards such a reality. Thus, by answering 
what our society ought to be, we can determine what to do. AD should be treated as aggressively 
as Cancer, even though Cancer can take people’s youth, Alzheimer’s can take people’s highly 
personal and valuable passage/experience towards death away. Furthermore, a society built on 
equality has far reaching implications, one of them being a right to a humane death and AD is a 13
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relentless foe to the very agency required for such a death to take place. AD leaves a vessel with 
the driver withered away over the years. Additionally, someone would be hard pressed to find 
fault in the acknowledgement that we should conduct as much research as possible now in order 
to mitigate needless future suffering. Also, it should be noted that costs spent now on AD 
research is money saved down the road in terms of healthcare. Health care costs can be directly 
from the AD patient or from the family of the individual. The burden of care can prove to be 
overwhelming and not all people are capable of handling such a scenario. Insufficient coping can 
lead to a malignant social psychology in the home (Sabat, S. R., 1994, Excess disability and 
malignant social psychology). 
 
Conclusion and future of AD 
The current opinion of many in the field has turned to the acceptance of AD as a 
multifactorial disease with the illness best characterized as the culmination of several etiological 
factors. The toxic medley serves to accelerate aging, leading to a bodily allostatic load. The new 
baseline of the body is thought to get to such an overwhelming degree that the brain can no 
longer function properly (Armstrong, 2013). While a large faction of the AD community 
suspects that AB aggregation is at the heart of the illness, to appropriately test the hypothesis an 
efficient treatment for its clearance must be put together.     
A bright future of treatments and medications fill the future of AD research with hope. 
Drug 2-hydroxypropyl-beta-cyclodextrin (HP-beta-cyclodextrin), may prove a potentially useful 
pharmacological tool. The drug’s effect comes through a mechanism that lowers cholesterol as 
well as possibly preventing AB production/oligomerization. Such a drug action may prove 
14
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beneficial for AD by tackling the lysosomal issue (Peric & Annaert, 2015). Currently, various 
drugs in the market are used to treat AD by merely alleviating symptoms, but there is a seriousn 
need to treat etiological effects, particularly because AD has a long asymptomatic phase (Rafii 
and Aisen, 2015). Very recent research aims at doing such a thing. Researchers have observed in 
animals that hibernate cold shock proteins such as RBM3 that may be of therapeutic value in 
patients with AD. The mechanism by which proteins re-fold at varying temperatures may prove 
to be key (Peretti, et.al. 2015). 
Additionally, antibody based treatment/medication, i.e. experimental drug solanezumab. 
This antibody-based medication specifically removes the amyloid-beta proteins which clump to 
form the sticky plaques. Early trials have shown beneficial (R.S. Doody et al. N. Engl. J. Med. 
370, 311-321; 2014; Elie Dolgin, How to Defeat Dementia: The three things that could help 
prevent a meltdown in health-care systems worldwide). In another study, intravenous 
administration of blood from young mice into old mice was shown to reverse loss of 
synaptophysin and calbindin, which are indicators of cognitive decline in people with AD as well 
as in the transgenic mouse model of the illness (Wyss-Coray, T., Aging, neurodegeneration and 
brain rejuvenation).  
Another critical intervention in the fight against AD is early screening. Early screening 
via PET imaging using 18F-florbetapir as the agent for imaging allows for an easier estimation 
of B-amyloid neuritic plaque density within the body. It has been estimated that early 
intervention that delays AD symptoms by only 5 years is can lead to a significant reduction of 
patients on the scale of 5.5 million by 2050, in the US alone (Hutton, M., et al., 2016. 
Therapeutic development for Alzheimer’s disease at Eli Lilly and Company). Lastly, an 
interesting note worth pursuing is how Cancer and AD are proving to set themselves as mutually 15
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exclusive. It would seem that manifestation of one serves to guard against manifestation of the 
other, by what means may be a beneficial inquiry in leading to cures for both (Catala and 
Seisdedos, 2014).  
Taking the compilation of AD research into account it would seem that there is need for 
greater clarity in classification of the illness. Perhaps AD should be seen as one disease amongst 
the public’s eye, possibly it should be taken even more broadly. A massive campaign against 
dementia in general could prove to garner support on the level of cancer. However, meticulous 
classification of the various nuanced yet unique illnesses must be enforced amongst academia in 
order to ensure maximal efficacy in research. In addition, although public appeal may be to 
generalize the illness that fact that the majority of AD come from environmental factors should 
still be accounted for. This can be done by emphasizing the environmental factors and their 
interplay with genetic susceptibility, i.e. hinting at epigenetics. Such a push could make for 
individuals to lead healthier lives, such as Paula Wolfert’s mentioned in a New York Times 
Article. Paula maintains a diet free of carbohydrates and centered on salmon, berries and greens, 
as well as turmeric extract, cinnamon and eggplant (New York Times. Kim Severson. March 
21st, 2017. Her Memory Fading, Paula Wolfert Fights Back With Food).  While such an extreme 
diet may not be committed to by the general public, any beneficial changes to their diets could 
ease their risk factors as well as stifle AD manifestation into later years.   
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